WEE1/PKMYT1 dual inhibitors vs. selective WEE1 drugs

The G2/M Checkpoint and CDK1 Regulation in Replication Stress-High Tumors

The G2/M checkpoint prevents cells with damaged or incompletely replicated DNA from entering mitosis — and in replication stress-high cancers, it is the primary survival mechanism that enables tumour cells to tolerate the genomic instability driven by oncogene activation, nucleotide depletion, and defective DNA repair pathways. Understanding how two kinases — WEE1 and PKMYT1 — cooperate to hold CDK1/Cyclin B in an inactive state is the foundation for appreciating why dual inhibition is mechanistically superior to targeting either kinase alone.

CDK1/Cyclin B is the master mitotic kinase. Its activity is held in check during S and G2 phases by inhibitory phosphorylation on two distinct residues: Threonine 14 (T14) and Tyrosine 15 (Y15). WEE1 is the dominant nuclear kinase responsible for Y15 phosphorylation, while PKMYT1 — localised primarily at the Golgi apparatus and endoplasmic reticulum — preferentially phosphorylates T14 and can additionally phosphorylate Y15 when Cyclin B is bound to CDK1. Both marks must be removed by CDC25 phosphatases for CDK1/Cyclin B to become fully active and drive the cell into mitosis.

Replication stress (RS) arises when DNA replication forks stall, slow down, or collapse. Many cancers exhibit intrinsically high RS — driven by oncogene activation (CCNE1 amplification, MYC amplification), homologous recombination deficiency (BRCA1/2 mutations), or RAS mutations. These tumours rely on robust G2/M checkpoint control to survive. This reliance creates a therapeutic vulnerability: if the checkpoint is fully abrogated in cells carrying unrepaired DNA, those cells are forced into catastrophic mitosis and die.

Why Selective WEE1 Inhibition Falls Short: The PKMYT1 Compensation Problem

Selective WEE1 inhibition with Adavosertib (AZD1775) has demonstrated clinical activity in replication stress-high tumours, particularly in combination with chemotherapy or in cancers with CCNE1 amplification and homologous recombination deficiency — but its efficacy is fundamentally constrained by a rapid compensatory mechanism centred on PKMYT1.

Upon WEE1 inhibition, cancer cells rapidly upregulate and rely on PKMYT1 activity to maintain inhibitory phosphorylation of CDK1, particularly on T14. PKMYT1 becomes the dominant kinase preventing CDK1/Cyclin B reactivation at the G2/M checkpoint. This compensatory mechanism allows cancer cells to maintain the G2/M arrest despite WEE1 inhibition, thereby evading mitotic catastrophe and cell death. Essentially, PKMYT1 acts as a bypass track for the inhibitory signal — one that Adavosertib cannot block.

“Upon WEE1 inhibition, PKMYT1 becomes the dominant kinase preventing CDK1/Cyclin B reactivation at the G2/M checkpoint — allowing cancer cells to maintain the G2/M arrest and evade mitotic catastrophe.”

This limitation is compounded by three additional factors. First, chronic exposure to selective WEE1 inhibitors can select for clones with upregulated PKMYT1 expression, creating acquired resistance. Second, because PKMYT1 compensation renders checkpoint abrogation incomplete — particularly in tumours where PKMYT1 expression or activity is inherently high — the therapeutic efficacy of Adavosertib in driving RS-high cells into fatal mitosis is substantially reduced. Third, selective WEE1 inhibition carries significant on-target toxicity in normal tissues, including bone marrow suppression and gastrointestinal effects, which limits therapeutic window and dosing intensity.

According to research published by Nature and validated by clinical data tracked through NIH clinical trial registries, the incomplete checkpoint abrogation from selective WEE1 inhibition is a well-documented phenomenon that correlates with reduced tumour response in preclinical RS-high models. The PKMYT1 compensation bypass is not merely a theoretical concern — it is the mechanistic rationale that drove the medicinal chemistry programme leading to Lunresertib.

Dual WEE1/PKMYT1 Inhibition: How Lunresertib Achieves Complete Checkpoint Abrogation

Lunresertib (RP-6306) overcomes the PKMYT1 compensation problem by simultaneously inhibiting both kinases responsible for CDK1 inhibitory phosphorylation — removing both the T14 and Y15 brakes on CDK1/Cyclin B activity in a single pharmacological intervention. This co-inhibition is not merely additive: it is mechanistically irreversible in its checkpoint consequences.

Complete Ablation of Inhibitory Phosphorylation

By inhibiting both WEE1 and PKMYT1, dual inhibitors prevent phosphorylation of both T14 and Y15 residues on CDK1. There is no remaining kinase capable of maintaining inhibitory phosphorylation to compensate for the loss of the other. CDC25 phosphatases can rapidly dephosphorylate any residual inhibitory marks, leading to uncontrolled and premature activation of CDK1/Cyclin B complexes. The G2/M checkpoint is catastrophically compromised.

Forced Mitotic Entry and Lethal Consequences

The simultaneous, uncontrolled activation of CDK1/Cyclin B forces cells harbouring high levels of replication stress and unrepaired DNA damage directly into mitosis. These cells are unprepared for chromosome segregation. The lethal consequences include premature chromosome condensation (PCC) — where DNA that has not finished replicating condenses prematurely, leading to shattered chromosomes (chromothripsis) — micronuclei formation from chromosome fragments, and ultimately mitotic catastrophe: failed chromosome alignment, spindle assembly checkpoint override, anaphase bridges, and cytokinesis failure resulting in cell death through apoptosis or necrosis.

Importantly, dual inhibition is inherently less susceptible to the primary adaptive resistance mechanism seen with selective WEE1 inhibitors. By targeting the compensatory pathway upfront, Lunresertib removes the bypass track before it can be utilised — offering a more robust and durable response in RS-high preclinical models.

Patent-Disclosed Structural Optimisation: Selectivity Over PLK1 and PAK4

The development of Lunresertib (RP-6306) by Repare Therapeutics, documented in patents WO2020/176646 and WO2021/016387, reveals a sophisticated medicinal chemistry campaign that achieved potent dual inhibition while maximising selectivity over other kinases — particularly PLK1, which was a major off-target liability of earlier compounds and would counterproductively antagonise the desired mechanism of forcing mitotic entry.

Core Scaffold and Hinge-Binding Motif

The structural campaign began with a pyrazolo[1,5-a]pyrimidine core — a heterocyclic scaffold providing optimal geometry for binding both WEE1 and PKMYT1 ATP pockets. Early compounds showed activity but lacked sufficient selectivity. The critical breakthrough was the identification of a 2-aminopyridine substituent at the C5 position of the core. This group forms crucial hydrogen bonds with the hinge region of both WEE1 (Cys379) and PKMYT1 (Met375), driving potency against both kinases simultaneously. The specific orientation and electronic properties of this hinge binder are essential to the dual activity profile.

The Morpholine Selectivity Bump

The defining selectivity feature disclosed in the patents is a morpholine — or morpholine-like substituent such as thiomorpholine dioxide in Lunresertib itself — attached meta to the hinge-binding aminopyridine group. This element was specifically engineered to exploit differences in the back pocket of WEE1/PKMYT1 compared to PLK1. In WEE1 and PKMYT1, the back pocket is relatively spacious and hydrophobic, accommodating the morpholine group with favourable hydrophobic contacts. In PLK1, the pocket is significantly narrower and more polar; the morpholine group acts as a steric bump, clashing with residues including Leu59 and creating unfavourable interactions that dramatically reduce PLK1 binding affinity.

Avoiding PLK1 inhibition is not merely a toxicity consideration — it is mechanistically critical. PLK1 inhibition causes severe mitotic arrest and would directly antagonise the intended therapeutic effect of forcing RS-high cancer cells through mitosis. The selectivity bump is therefore both a safety and an efficacy feature. According to structural biology data tracked by RCSB PDB and kinase selectivity profiling reported through EMBL-EBI, the back-pocket topology differences between WEE1/PKMYT1 and PLK1 are well-characterised and amenable to this type of steric discrimination.

C3 Substituent and Physicochemical Tuning

Substituents at the C3 position of the pyrazolopyrimidine core — including small alkyl groups such as methyl in Lunresertib, or solubilising groups like dimethylamine in some analogues — were tuned to improve physicochemical properties including solubility and membrane permeability, and to optimise pharmacokinetics while maintaining the dual activity and selectivity profile. The choice of thiomorpholine dioxide over plain morpholine in Lunresertib specifically offers enhanced aqueous solubility — a critical drug-like property for clinical development. Patents also document selectivity optimisation against PAK4, where the specific steric and electronic features around the hinge binder and morpholine bump minimise interactions with PAK4’s unique ATP pocket geometry.

The patents also reveal that the selectivity bump strategy was validated through extensive structure-activity relationship (SAR) campaigns. The thiomorpholine dioxide group in Lunresertib offers enhanced aqueous solubility compared to plain morpholine — addressing a key physicochemical liability in the earlier series — while retaining the critical steric clash with PLK1 and maintaining favourable contacts within the WEE1 and PKMYT1 back pockets. This dual role of the selectivity element (both a selectivity determinant and a solubility enhancer) represents a particularly elegant aspect of the structural optimisation programme, as documented in PatSnap’s innovation intelligence resources.

Clinical Implications and Combination Strategies for Replication Stress-High Cancers

The structural optimisations leading to Lunresertib translate directly into potential clinical advantages over Adavosertib — and the mechanistic rationale for dual inhibition opens combination strategies that selective WEE1 inhibition cannot access.

Enhanced Efficacy and Broader Applicability

By completely abrogating the G2/M checkpoint via dual mechanism, Lunresertib shows superior preclinical activity compared to Adavosertib in models with high replication stress, including those with CCNE1 amplification, homologous recombination deficiency, and other RS drivers. Early clinical data from the LUNAR trial (NCT04855656, Phase 1/2) shows promising monotherapy activity in these populations. Dual inhibition may also be effective in tumours where selective WEE1 inhibition has limited activity due to inherent PKMYT1 dependency or rapid compensatory upregulation — broadening the eligible patient population.

Combination Strategies

Lunresertib is being actively explored in several combination approaches. With PARP inhibitors, dual WEE1/PKMYT1 inhibition demonstrates synergy in HRD tumours (BRCA1/2 mutant), where PARP inhibitor treatment induces replication stress and dual inhibition prevents recovery in G2 — targeting a key resistance mechanism to PARP inhibitor therapy. With DNA damaging agents and ATR inhibitors, the combination targets complementary nodes in the replication stress response: ATR is the upstream master regulator of the RS response (including CHK1 activation, which stabilises WEE1), and combining ATR inhibition with dual WEE1/PKMYT1 inhibition creates a particularly potent synthetic lethal axis. These approaches are consistent with the combination strategies tracked in clinical trial databases maintained by NIH and regulatory bodies including EMA.

Improved Therapeutic Index

The high selectivity of Lunresertib — particularly the avoidance of PLK1 inhibition — is anticipated to reduce toxicity related to off-target effects such as PLK1-driven myelosuppression, while ensuring the therapeutic mechanism (forced mitotic entry) is not blocked. Avoiding PLK1 also ensures that the drug does not counteract its own mechanism by inducing spindle assembly checkpoint activation, which would prevent the mitotic catastrophe that is the intended therapeutic outcome. The PatSnap drug discovery intelligence platform enables detailed tracking of these selectivity profiles across the competitive landscape.

“Dual inhibition is inherently less susceptible to the primary adaptive resistance mechanism seen with selective WEE1 inhibitors — by targeting the PKMYT1 compensatory pathway upfront, Lunresertib removes the bypass track before it can be utilised.”